checkAd

    Novavax - Vergessene Aktie feiert ein Comeback. Gute Chancen dank aktueller Nachrichtenlage - Älteste Beiträge zuerst (Seite 106)

    eröffnet am 25.04.09 09:22:26 von
    neuester Beitrag 15.03.24 15:56:36 von
    Beiträge: 22.761
    ID: 1.149.910
    Aufrufe heute: 2
    Gesamt: 1.224.196
    Aktive User: 0


     Durchsuchen
    • 1
    • 106
    • 2277

    Begriffe und/oder Benutzer

     

    Top-Postings

     Ja Nein
      Avatar
      schrieb am 22.12.13 12:47:50
      Beitrag Nr. 1.051 ()
      Antwort auf Beitrag Nr.: 46.069.436 von Betterway am 18.12.13 07:40:12Ditto...:rolleyes:
      Avatar
      schrieb am 22.12.13 12:50:21
      Beitrag Nr. 1.052 ()
      Avatar
      schrieb am 28.02.14 12:19:35
      Beitrag Nr. 1.053 ()
      Novavax Announces Extension of Contract for Advanced Development of Recombinant Influenza Products and Pandemic Preparedness with HHS-BARDA
      Gaithersburg, MD – (February 27, 2014)–/GlobeNewswire/Novavax, Inc. (Nasdaq: NVAX) announced today the execution of a contract modification to extend the base period of performance of its current contract with the U.S. Department of Health and Human Services, Biomedical Advanced Research and Development Authority (BARDA) for the advanced development of Novavax’ recombinant seasonal and pandemic influenza vaccines. The contract was originally awarded in February 2011, with funding of up to $97 million over an initial base period ending in February 2014. Novavax and BARDA have agreed to amend the agreement to allow Novavax to continue to access the remainder of the $97 million in base period funding through September 2014. These funds will support the upcoming Phase 2 trial for our H7N9 vaccine candidate with Matrix-M, and activities relating to our quadrivalent seasonal influenza vaccine. BARDA has the ability to dedicate up to $79 million in additional funds to support Novavax’ later-stage development of these vaccines, during an option period currently anticipated to add two years to the overall performance period.
      “Development of our seasonal and pandemic influenza products during the last three years under our contract with BARDA has allowed us to refine and develop influenza vaccine products while delivering important clinical trial results from our seasonal quadrivalent, avian H5N1, and most recently, avian H7N9 studies. While our original development plans anticipated utilizing the full amount of the contracted base-period funding within the three-year period, certain scope changes and development efforts resulted in delayed development timelines. Extending the base period allows us to continue to access the remaining base period budget as we initiate a pandemic H7N9 Phase 2 study early this year and prepare for additional Phase 2 and Phase 3 influenza clinical trials, which we expect would occur during the contract’s option period,” said Stanley C. Erck, the company’s CEO and President.
      1 Antwort?Die Baumansicht ist in diesem Thread nicht möglich.
      Avatar
      schrieb am 16.10.14 23:41:38
      Beitrag Nr. 1.054 ()
      Antwort auf Beitrag Nr.: 46.540.991 von gutdrauf9 am 28.02.14 12:19:35Novavax Study Published in Vaccine
      RSV F-Protein Nanoparticle Vaccine Induces Antigenic Site II Antibodies

      Nachrichtenquelle: GlobeNewswire
      | 15.10.2014, 14:33 | 131 Aufrufe | 0 | druckversion

      ◦Vaccinated Animals Generated a Broad Spectrum of Protective Antibodies
      ◦Vaccine Induces Antibodies that are at Least as Protective as Palivizumab
      ◦Palivizumab Competing Antibody Response from Vaccine Protects Against Both Homologous and Heterologous Disease Strains

      GAITHERSBURG, Md., Oct. 15, 2014 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants, today announced that its RSV F-protein nanoparticle vaccine candidate (RSV F Vaccine) evoked a polyclonal antibody response to antigenic site II, the same site targeted by the monoclonal antibody palivizumab (Synagis®), resulting in protection from an RSV challenge in an animal model. Researchers at Novavax reported these findings in an online paper published by Vaccine titled: "An insect cell derived respiratory syncytial virus (RSV) F nanoparticle vaccine induces antigenic site II antibodies and protects against RSV challenge in cotton rats by active and passive immunization."

      "This study further characterizes the immune response to our RSV F Vaccine, including the production of both polyclonal palivizumab competing antibodies that target antigenic site II, as well as other neutralizing antigenic sites on the F-protein," said Greg Glenn, SVP, Research and Development at Novavax. "In addition, our ability to assess the safety of our RSV F Vaccine relative to Lot 100 formalin inactivated vaccine, which is known to cause disease enhancement, and to demonstrate that our vaccine's efficacy is equivalent or better than palivizumab, gives us greater confidence that our RSV vaccine candidate will be both safe and effective."

      RSV is the number one cause of hospitalization in infants ages 0 to 12 months in the U.S. and is a significant cause of infant morbidity and mortality globally. The only approved product in the U.S. for the prevention of RSV disease in this population is palivizumab, marketed as Synagis® by MedImmune/AstraZeneca. Palivizumab binds to a specific domain on the RSV F-protein known as antigenic site II, blocking viral fusion and preventing infection. Novavax has developed a novel RSV vaccine candidate based on the expression of a mature form of the RSV F-protein, which exposes the antigenic site II for processing by the immune system. The resulting immune response produces polyclonal antibodies that have been shown to compete with palivizumab for the antigenic site II binding domain, referred to as palivizumab-competing antibodies or PCA.

      The study employed a number of antibody assays to further explore the immunogenicity of the RSV F Vaccine and the production of vaccine-induced PCA in the cotton rat model. These studies used palivizumab as a control, to assess relative potency of the vaccine, both in active and passive assessments, and the recently available Lot 100 formalin-inactivated RSV vaccine, which historically enhanced RSV disease in clinical studies. This allowed comparative evaluation of safety, 'functional' immunity as measured by PCA and neutralization assays, and protection in this clinically relevant model. The vaccine was shown to be safe, potent, to elicit high levels of neutralizing PCA and anti-F antibodies and to be protective against both homologous strain and heterologous, or "drift", strain viral challenges. The protection seen with active immunization could be reproduced using passively injected immune sera and appeared as potent as, or more potent than palivizumab. Neither active immunization of vaccine nor passively injected immune sera were associated with disease enhancement. Finally, the RSV F Vaccine was also found to elicit antibodies that are known to bind other non-palivizumab F-protein binding sites associated with neutralization.

      About RSV

      RSV is a major respiratory pathogen in infants, children, and adults. RSV infections in adults represent re-infections and are generally mild to moderate in severity, except in persons with high-risk conditions including the elderly and adults with underlying chronic cardiac or pulmonary disease. It is estimated that between 11,000 and 17,000 adults die of RSV infection annually in the U.S. and up to 180,000 are admitted to hospitals with respiratory symptoms. Currently, there is no approved RSV prophylactic vaccine available. Palivizumab is a monoclonal antibody, licensed and sold by MedImmune as Synagis®, that targets the RSV F protein and is used for prophylaxis against RSV disease in high risk infants.

      About Novavax

      Novavax, Inc. (Nasdaq:NVAX) is a clinical-stage biopharmaceutical company creating novel vaccines and vaccine adjuvants to address a broad range of infectious diseases worldwide. Using innovative proprietary recombinant nanoparticle vaccine technology, the company produces vaccine candidates to efficiently and effectively respond to both known and newly emergent diseases. Additional information about Novavax is available on the company's website, novavax.com.

      Novavax Forward-Looking Statements

      Statements herein relating to the future of Novavax and the ongoing development of its vaccine and adjuvant products are forward-looking statements. Novavax cautions that these forward looking statements are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those expressed or implied by such statements. These risks and uncertainties include those identified under the heading "Risk Factors" in the Novavax Annual Report on Form 10-K for the year ended December 31, 2013, filed with the Securities and Exchange Commission (SEC). We caution investors not to place considerable reliance on the forward-looking statements contained in this press release. You are encouraged to read our filings with the SEC, available at sec.gov, for a discussion of these and other risks and uncertainties. The forward-looking statements in this press release speak only as of the date of this document, and we undertake no obligation to update or revise any of the statements. Our business is subject to substantial risks and uncertainties, including those referenced above. Investors, potential investors, and others should give careful consideration to these risks and uncertainties.
      CONTACT: Barclay A. Phillips
      SVP, Chief Financial Officer and Treasurer
      Novavax, Inc.
      240-268-2000
      Avatar
      schrieb am 27.10.14 15:05:25
      Beitrag Nr. 1.055 ()
      Novavax wird seit heute in amerikanischen Foren als neuer "Ebola player" gehandelt.

      Ausserdem gab es wichtige Daten am WE zu einem weiteren Impfstoff.
      4 Antworten?Die Baumansicht ist in diesem Thread nicht möglich.

      Trading Spotlight

      Anzeige
      Der Final Countdown: Hier heute noch rein!? Große Meldung angekündigt…mehr zur Aktie »
      Avatar
      schrieb am 30.10.14 17:32:27
      Beitrag Nr. 1.056 ()
      Avatar
      schrieb am 30.10.14 17:35:38
      Beitrag Nr. 1.057 ()
      Antwort auf Beitrag Nr.: 48.142.061 von jimco am 27.10.14 15:05:25
      Zitat von jimco: Novavax wird seit heute in amerikanischen Foren als neuer "Ebola player" gehandelt.

      Ausserdem gab es wichtige Daten am WE zu einem weiteren Impfstoff.


      http://www.nasdaq.com/symbol/nvax/institutional-holdings
      Avatar
      schrieb am 31.10.14 15:09:08
      Beitrag Nr. 1.058 ()
      Antwort auf Beitrag Nr.: 48.142.061 von jimco am 27.10.14 15:05:25
      Zitat von jimco: Novavax wird seit heute in amerikanischen Foren als neuer "Ebola player" gehandelt.

      Ausserdem gab es wichtige Daten am WE zu einem weiteren Impfstoff.


      http://finance.yahoo.com/news/novavax-announces-ebola-vaccin…;)
      2 Antworten?Die Baumansicht ist in diesem Thread nicht möglich.
      Avatar
      schrieb am 14.11.14 12:35:20
      Beitrag Nr. 1.059 ()
      Antwort auf Beitrag Nr.: 48.187.465 von gerdass am 31.10.14 15:09:08
      Zitat von gerdass:
      Zitat von jimco: Novavax wird seit heute in amerikanischen Foren als neuer "Ebola player" gehandelt.

      Ausserdem gab es wichtige Daten am WE zu einem weiteren Impfstoff.


      http://finance.yahoo.com/news/novavax-announces-ebola-vaccin…;)


      Hallo an alle investierten!
      Das mit dem EbolaPlayer würde ich nicht zu hoch bewerten! den ist es doch soo das Jährlich mehr an einer "gewöhnlichen" Grippe sterben als jz an Ebola erkranken! Nicht das ich dies klein reden will überhaupt nicht! Nur hier für den Aktienkurs wirds woll kaum erwähnenswert. Anders wäre es wohl bei einem Mittel gegen Krebs,Aids odr Diabetes etc. ! Oder halt eben gegen Grippe, wo Jahr für Jahr Millionen leiden - schau ma mal , ich finds ne gute Sache hier investiert zu sein - auch wenn das Risiko hoch ist! es kann sich von einem Tag auf den anderen ändern.
      1 Antwort?Die Baumansicht ist in diesem Thread nicht möglich.
      Avatar
      schrieb am 25.11.14 11:09:09
      Beitrag Nr. 1.060 ()
      Antwort auf Beitrag Nr.: 48.320.233 von ShinCHan am 14.11.14 12:35:20
      Zitat von ShinCHan: Das mit dem EbolaPlayer würde ich nicht zu hoch bewerten! den ist es doch soo das Jährlich mehr an einer "gewöhnlichen" Grippe sterben als jz an Ebola erkranken! Nicht das ich dies klein reden will überhaupt nicht! Nur hier für den Aktienkurs wirds woll kaum erwähnenswert.


      BB Biotech sieht das etwas anders und die sind bei ihren Beteiligungen nun wirklich äußerst erfolgreich:
      Neuartige Impfstoffe
      Das US-Unternehmen Novavax spezialisiert sich auf die Entwicklung
      neuartiger Impfstoffe. Aktuell am weitesten fortgeschritten
      sind die Forschungsarbeiten an einem Impfmittel zur Prävention
      der sogenannten RSV-Infektion bei Neugeborenen und älteren
      Menschen. RSV ist eine lebensbedrohliche Infektion der Atemwege.
      Die Antikörper werden von der Mutter auf das Baby übertragen,
      in den USA wird eine solche Impfung bereits bei rund
      50% der Schwangeren durchgeführt. RSV stellt eine der häufigsten
      Ursachen für einen Krankenhausaufenthalt von Babys dar, die
      Impfung bringt daher auch eine deutliche Senkung der Folge kosten
      für das Gesundheitssystem mit sich. Für ältere Menschen entwickelt
      Novavax ein Kombinationspräparat für RSV und Influenza.
      Profiteur der Ebola-Panik
      Die Impfstoff-Plattform lässt sich zudem auf weitere Bereiche
      anwenden. So konnte Novavax auf der Vaccine and ISV Conference
      in Philadelphia dieses Jahr einen ersten Impfstoff gegen Ebola
      präsentieren. Der Wirkstoff basiert auf dem Typus Ebola, wie er
      2014 in Guinea aufgetreten ist. Lydia Bänziger von BB Biotech sieht
      enorme Chancen in der Beteiligung: „Wir erkennen einen klaren
      Bedarf an einem RSV-Impfstoff und sehen Novavax als optimal
      positioniert, um diesen Markt abzudecken. Zudem hat das Unternehmen
      eine versatile Plattform, mit der
      sie schnell neue Impfstoffkandidaten hervorbringen
      kann, wie ihre Kandidaten für
      H7N9 und Ebola zeigen.“ Die Aktie von
      Novavax ist seit dem Investment von BB
      Biotech bereits deutlich angestiegen, nicht
      zuletzt auch aufgrund der in den USA
      grassierenden Ebola-Panik.

      Quelle: http://www.bbbiotech.ch/index.php?eID=tx_nawsecuredl&u=4&g=1…
      • 1
      • 106
      • 2277
       Durchsuchen


      Beitrag zu dieser Diskussion schreiben

      Investoren beobachten auch:

      WertpapierPerf. %
      -0,73
      -0,79
      -3,16
      +1,52
      +6,25
      -2,40
      +2,66
      +0,39
      +0,55
      -2,66
      Novavax - Vergessene Aktie feiert ein Comeback. Gute Chancen dank aktueller Nachrichtenlage